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physiologically significant mechanistic
link between these pathways and could
open avenues to new therapeutic ap-
proaches. In particular, the protective
effects of supplementation with HBP
metabolites may represent a promising
therapeutic strategy.
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Microbial and danger signals result in inflammasome activation and release of inflammatory
cytokines through mechanisms that remain elusive. Cai et al. and Lu et al. show that triggering of
inflammasome sensors induces prion-like polymerization of the adaptor ASC into filaments. These
structures function as platforms for inflammatory cytokine production and represent a unified
mechanism for inflammasome assembly.Inflammasomes are key signaling ma-
chines of the innate immune system that
drive the production of the highly inflam-
matory cytokine interleukin-1b (IL-1b)
via caspase-1 activation in response to
microbial and nonmicrobial danger sig-
nals (Schroder and Tschopp, 2010).
They are composed of a danger sensor,
an adaptor protein—often ASC—and
caspase-1. Prototypical inflammasome
sensors, such as NLRP3 and AIM2,
contain a pyrin domain (PYD) that can
interact with the PYD of ASC (ASCPYD),
and ASC additionally possesses a cas-
pase recruitment domain (CARD) for
procaspase-1 engagement. Although the
primary composition of the inflamma-
somes has been resolved and much
of their physiological and pathological
functions have been revealed throughgenetic studies, the biochemical and
biophysical mechanisms of inflamma-
some activation remained mysterious. In
this issue of Cell, two elegant reports
demonstrate that AIM2 or NLPR3 trig-
gering induces a prion-like polymerization
of ASC into filaments that provide plat-
forms for activating inflammatory cytokine
production (Cai et al., 2014; Lu et al.,
2014).
Prions were originally identified as the
causative agents of spongiform encepha-
lopathies in humans, but additional
studies found prions also in lower organ-
isms such as yeast (Prusiner, 1998).
These proteins are functionally defined
by their ability to induce an energetically
favored self-polymerization process in
which an initial nucleation step converts
the native protein into the polymerizedform. The Chen laboratory previously
identified the immune adaptor MAVS as
the first beneficial prion-like protein in
mammals (Hou et al., 2011). After innate
virus sensing, the RNA receptor RIG-I nu-
cleates the N-terminal CARD of MAVS,
which then undergoes prion conversion
resulting in MAVS polymerization,
NF-kB, and IRF3 activation. Now, the
same group uses a yeast system to
screen for prion-like features in additional
immune signaling proteins that contain
death domain (DD) folds, such as a PYD
or CARD (Cai et al., 2014). By replacing
the prion domain (NM) of the yeast
Sup35 prion with candidate domains,
the authors observe that the ASCPYD ex-
hibits remarkable prion-forming abilities.
Interestingly, NLRP3PYD and AIM2 induce
ASCPYD prion conversion, and both AIM2, March 13, 2014 ª2014 Elsevier Inc. 1127
Figure 1. A Unified Model for Inflammasome Assembly
In nonstimulated cells, the inflammasome sensors AIM2 and NLRP3 exist in an autoinhibited state.
Triggering of AIM2 via intracytoplasmic DNA delivery or activation NLRP3 by multiple distinct stimuli
overcome autoinhibition of the inflammasome sensors and allow their PYDs to interact with the PYD of the
adaptor protein ASC. These events result in an ASC prion nucleation, which subsequently templates other
ASCmolecules to induce a self-perpetuating polymerization cascade that assembles ASCmolecules into
large fibers. Through CARD-CARD interactions between ASC and procaspase-1, the ASC polymers
recruit multiple caspase-1 molecules to drive proximity-induced caspase-1 dimerization and polymeri-
zation, resulting in autocatalytic activation of its p10 and p20 subunits for inflammation.and NLRP3 convert full-length ASC
(ASCFL) into a self-perpetuating prion. In
reverse experiments, they test whether
the yeast prion domain can functionally
replace ASC modules in inflammasome
activation in mammalian cells. Indeed,
NM-ASCCARD, but not NM-ASCPYD, trig-
gers caspase-1 activation and pro-IL-1b
processing, indicating that prion-like
conversion of chimeric molecules with
an ASCCARD effector domain is sufficient
for inflammasome activation. Analyses of
multiple ASCPYD point mutants for prion-
formation and their ability to generate
mature IL-1b find that only those mutants
that form self-perpetuating prions in yeast
mediate caspase-1 activation and IL-1b1128 Cell 156, March 13, 2014 ª2014 Elsevieproduction upon canonical NLPR3 activa-
tion in mammalian cells. Finally, the
authors found that converted prion-like
ASCPYD fibers are sufficient to trigger
a catalytic self-perpetuating ASCFL poly-
merization that results in inflammasome
activation.
Lu and colleagues use a comple-
mentary approach to investigate inflam-
masome assembly (Lu et al., 2014). By
electron microscopy (EM), they observe
that AIM2PYD/ASCPYD complexes form
uniform filaments in which the AIM2PYD
is localized to the end. Quantitative poly-
merization analysis establishes that,
although ASCPYD can polymerize alone,
the presence of AIM2PYD increases ther Inc.ASCPYD polymerization rates dramati-
cally. When full-length AIM2FL is added,
a strong increase in the ASCPYD polymer-
ization is observed after dsDNA addition,
which releases AIM2FL from intramolecu-
lar autoinhibition. NLRP3PYD-NBD frag-
ments, which lack the NLRP3 autoinhibi-
tory leucine rich repeats (LRRs), also act
as powerful inductors of ASCPYD poly-
merization, and NLRP3 localizes also
to the end of ASC filaments. A near-
atomic-resolution structural model of the
ASCPYD polymer demonstrates hollow
filaments with three major interfaces
between ASCPYD subunits. Structural
models of the AIM2PYD/ASCPYD and
NLRP3PYD/ASCPYD associations addi-
tionally show that the PYDs of AIM2 or
NLRP3 continue the helical arrangement
of ASCPYD filaments, and site-directed
mutagenesis reveals that a proper con-
tact between the AIM2PYD and ASCPYD
or the NLRP3PYD and ASCPYD is essential
to nucleate ASCPYD polymerization by the
inflammasome sensor. Finally, the whole
AIM2PYD, ASCFL, and Caspase-1CARD
inflammasome complex was assembled
in vitro and analyzed for its stoichiometric
composition and microscopic structure.
Within the complex, relative few AIM2
molecules are present compared to
ASC, and ASC is understoichiometric to
caspase-1. The whole ternary complex
is star shaped with ASC in the center
and caspase-1 at the arms, and com-
parable inflammasome structures are
observed within mammalian cells.
These two studies support a unified
model for ASC-dependent inflamma-
some activation (Figure 1). After an insult
reaches a threshold, NLRP3 or AIM2 are
released from autoinhibition, allowing
interaction of their PYD with the PYD of
ASC. These events result in ASC prion-
like nucleation, which perpetuates inde-
pendently of the nucleating factor to
form large stable ASC filaments that are
both required and sufficient for inflam-
masome activation. The PYDs of ASC
acts as the building block of the fila-
ments, and the CARDs are flexibly linked
to induce pro-caspase-1 polymerization
and activation. Because relative few
sensor molecules are sufficient to induce
polymerization of relative large numbers
of ASC and caspase-1 molecules and
because the process is self-propagating,
this mechanism allows robust signal
amplification. The principle of prion-like
polymerization seems to be conserved
in signal transduction because a fungal
NOD-like pattern recognition receptor
also induces conversion of a fungal prion
(Cai et al., 2014). Moreover, filamentous
signaling complexes with DD modules
are observed in other inflammatory cas-
cades such as antigen receptor signaling
through CARD11/BCL10/MALT1 (Qiao
et al., 2013) or in the Rig-I/MAVS
pathway (Hou et al., 2011). Still, many
DD-containing immune adapters, in-
cluding MyD88, do not form unrestrained
polymers but rather form limited oligo-
mers with presumably reversible organi-
zation (Lin et al., 2010). The biophysical
characteristics that dictate limited olig-
omer versus self-propagating polymer
formation remain to be defined.
Of note, not all inflammasomes utilize
ASC. The sensor NLRC4, for instance,
can activate caspase-1 independent of
ASC after Salmonella typhimurium infec-tion. Whether such mechanisms also
involve prion-like protein conversion is
unclear. Finally, because aberrant inflam-
masome activation is deleterious to the
host (Schroder and Tschopp, 2010), it
must be counterbalanced to maintain
homeostasis. Classical inflammatory
pathways that are controlled by pro-
tein kinases or ubiquitin ligases are
negatively regulated via phosphatases
and de-ubiquitinases (Ruland, 2011).
The literature indicates that selective
autophagy could remove filamentous
CARD11/BCL10/MALT1 signalosomes
after T cell activation (Paul et al., 2012).
In the future, it will be important to define
whether similar mechanisms could also
disassemble activated inflammasomes.ACKNOWLEDGMENTS
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Synonymous mutations do not alter amino acids and are generally considered nonfunctional in
cancer. Supek et al. now present a compelling analysis suggesting that such silent mutations
can be oncogenic by altering transcript splicing and thereby affecting protein function.Sporadic cancer is thought to arise from a
cell of origin with accumulated somatic
mutations. With thousands of cancer
genomes and exomes sequenced, dif-
ferent categories of genomic alterations,
such as somatic point mutations, loss
or gain of chromosome material, and
structural genome rearrangements, have
been identified by comparing DNA from
tumor cells with that from matching
normal tissues. Point mutations are clas-
sified as synonymous versus nonsynony-mous based on their ability to alter the
encoded amino acids and thus affect
protein function. Synonymous or silent
mutations are categorized as passenger
events because they do not modify the
protein sequence and are thus consid-
ered functionally irrelevant, although their
potential involvement in tumorigenesis
has been suspected (Gartner et al.,
2013). In this issue, Ben Lehner and col-
leagues revisit this common perception
of synonymous mutations in cancer(Supek et al., 2014). By analyzing the
catalog of somatic mutations detected in
3,851 cancer exomes and more than
400 whole genomes from 19 tumor types,
they observed a 1.23- to 1.3-fold enrich-
ment of silent mutations in oncogenes,
but not in tumor suppressor genes,
when compared to a set of noncancer
genes with matching genomic features,
including GC content, mRNA expression
levels across tissues, and replication
timing. As a reference, the enrichment, March 13, 2014 ª2014 Elsevier Inc. 1129
